Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Pfizer Inc (PFE) Price & Performance

Flagstar Bank NATrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Pfizer Inc — how do they compare? Flagstar Bank NA trades at $15.4 (market cap $6.26B), while Pfizer Inc trades at $25.1 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 22.6× Flagstar Bank NA's market cap, and Pfizer Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.

FLGPFE
Market Cap
$6.26B$141.46B
Sector
FinancialsHealth
52-Week High
$15.28$28.56
52-Week Low
$10.72$23.29
Dividend Yield
0.27%6.93%
Volume
29,869,932
Enterprise Value
$192.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $15.36, up 2.67% today, with a bullish technical signal from moving averages. The stock shows improving fundamentals, with two consecutive quarterly EPS beats and a positive Q1 2026 net income. The company is executing a turnaround, highlighted by a proprietary technology transformation and a credit rating upgrade. The price trades below the consensus target of $17.05, with a price-to-book ratio of 0.82 suggesting potential undervaluation.

The outlook is cautiously optimistic, supported by analyst consensus and recent profitability. Key opportunities include continued operational improvement and capital returns. Risks involve the ongoing turnaround execution, net negative cash flow, and sensitivity to interest rates. The stock presents a value proposition if the bank sustains its recovery trajectory.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE